Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOVALDI vs EPCLUSA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is converted to the active triphosphate form (GS-461203) that competes with natural nucleotides and causes chain termination upon incorporation into viral RNA.
EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.
Treatment of chronic hepatitis C virus (HCV) infection as a component of a combination antiviral regimen (FDA approved),Off-label: Treatment of HCV in patients with hepatocellular carcinoma awaiting liver transplantation
Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years and older,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection without cirrhosis or with compensated cirrhosis,Treatment of genotype 1, 2, 3, 4, 5, or 6 HCV infection with decompensated cirrhosis (in combination with ribavirin)
400 mg orally once daily with or without food.
400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.
Terminal half-life of sofosbuvir is approximately 0.4-0.5 hours; the predominant circulating metabolite GS-331007 has a terminal half-life of 27 hours. This long half-life supports once-daily dosing.
Sofosbuvir: 0.4 hr (parent), 27 hr (GS-331007); Velpatasvir: 15 hr. Clinical context: once-daily dosing achieves steady-state in ~1 week.
Sofosbuvir is a prodrug that undergoes extensive hepatic metabolism to form the active triphosphate. It is metabolized by cathepsin A (Cat A) and carboxylesterase 1 (CES1), followed by phosphorylation by nucleoside kinases. The inactive metabolite GS-331007 is eliminated renally.
Sofosbuvir is metabolized in the liver to its active metabolite (GS-461203) via cathepsin A (Cat A) and CES1, followed by phosphorylation. Velpatasvir is metabolized primarily by CYP2B6, CYP2C8, and CYP3A4.
Primarily fecal (77% of absorbed dose as metabolites, 3.5% as unchanged drug) with minor renal elimination (3.5% total, mainly metabolites). Biliary excretion contributes to fecal elimination.
Sofosbuvir: 80% renal (as inactive metabolite GS-331007), 14% fecal; Velpatasvir: 94% fecal, 0.4% renal.
Sofosbuvir is 61-65% bound to human plasma proteins; the metabolite GS-331007 has minimal protein binding (<1%).
Sofosbuvir: 61-65% (human plasma proteins); Velpatasvir: >99.5% (mainly albumin, alpha-1 acid glycoprotein).
Sofosbuvir: approximately 0.25 L/kg (based on 80 kg individual, Vd ~20 L), suggesting limited extravascular distribution. GS-331007: Vd is not clinically relevant as it is inactive.
Sofosbuvir: ~69 L (calculated as Vd/F); Velpatasvir: ~130 L (calculated as Vd/F). Not typically expressed per kg; indicates extensive tissue distribution.
Oral bioavailability of sofosbuvir is not precisely determined but is adequate for therapeutic effect; absorption is enhanced by food (high-fat meal increases AUC by ~1.8-fold).
Sofosbuvir: ~92% (oral, with food); Velpatasvir: ~25% (fasted), increased with high-fat meal (up to 2-fold).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease requiring hemodialysis, no prospective data; may use with caution but insufficient data to recommend dose adjustment.
No dose adjustment required for GFR ≥30 m L/min. Safety and efficacy not established for GFR <30 m L/min or hemodialysis; use with caution and consider alternative therapy.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for use in patients with severe hepatic impairment (Child-Pugh C) due to significantly increased exposure and potential toxicity; contraindicated.
No dose adjustment for mild or moderate hepatic impairment (Child-Pugh A or B). Not recommended for use in severe hepatic impairment (Child-Pugh C) due to higher exposures of velpatasvir.
Approved for patients aged 3 years and older: weight <17 kg: 150 mg orally once daily; weight 17 to <35 kg: 200 mg orally once daily; weight ≥35 kg: 400 mg orally once daily; administer with food.
For patients ≥6 years old or weighing ≥17 kg: fixed-dose combination (400 mg/100 mg) once daily with or without food, regardless of weight, for 12 weeks. Safety and efficacy not established for children <6 years or weighing <17 kg.
No specific dose adjustment required for elderly patients; dosing based on hepatic and renal function with consideration of age-related decline in renal function. Monitor for adverse events as elderly may have higher risk of comorbidities and concomitant medications.
No specific dose adjustment required based on age; use same dosing as younger adults, with monitoring for comorbidities and potential drug interactions.
NOT APPROVED BY FDA FOR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION. WAIT, SOVALDI IS APPROVED. CORRECTION: No black box warning for Sovaldi (sofosbuvir) as a single agent. However, when used in combination with other antivirals, there is a risk of hepatitis B virus (HBV) reactivation. The FDA has issued a boxed warning regarding HBV reactivation for direct-acting antivirals, including sofosbuvir-containing regimens.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV. Test all patients for evidence of current or prior HBV infection before initiating treatment. Monitor for HBV reactivation during and after treatment.
Risk of hepatitis B virus reactivation in patients coinfected with HBV and HCV, which can lead to fulminant hepatitis and death.,Symptomatic bradycardia when used with amiodarone, especially in patients also taking beta-blockers or with underlying cardiac comorbidities.,Reduced efficacy in patients with genotype 3 HCV infection when used without ribavirin.,Use with caution in patients with severe renal impairment (e GFR <30 m L/min) or end-stage renal disease due to increased exposure of the metabolite GS-331007.
Risk of HBV reactivation in patients coinfected with HCV and HBV,Increased risk of bradycardia when used with amiodarone, especially in patients on beta-blockers or with cardiac comorbidities,Possible decreased therapeutic effect with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort),Not recommended in patients with severe renal impairment (e GFR <30 m L/min) or end-stage renal disease requiring dialysis
Hypersensitivity to sofosbuvir or any component of the formulation,Coadministration with potent P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort) which may significantly reduce sofosbuvir efficacy
Concomitant use with amiodarone (risk of symptomatic bradycardia),Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort)
No significant food interactions. May be taken with or without food. Grapefruit or other fruit juices have no known clinically relevant interaction with sofosbuvir.
Take with or without food. No specific dietary restrictions. Avoid grapefruit juice? No interaction reported. Avoid alcohol as it can worsen liver disease.
Sovaldi (sofosbuvir) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity at exposures up to 10 times the human therapeutic dose. However, human data are limited. In animal reproduction studies, no fetal harm was observed in rats and rabbits at exposures 10 and 5 times the human exposure, respectively. No dose-limiting maternal or fetal toxicity was noted in rats or rabbits. The risk of teratogenicity in humans is considered low, but because of limited human data, use during pregnancy should only be if clearly needed. Ribavirin, which is commonly used in combination with sofosbuvir for chronic hepatitis C, is contraindicated in pregnancy due to its known teratogenic and embryocidal effects (Pregnancy Category X). Therefore, concomitant use of ribavirin imposes significant fetal risk, especially during the first trimester.
EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there are no adequate human data; animal studies show no evidence of teratogenicity at clinically relevant exposures. However, due to the potential for ribavirin co-administration in some HCV regimens, pregnancy must be excluded before initiation and avoided during treatment and for 6 months after in females of childbearing potential.
It is not known whether sofosbuvir or its metabolites are excreted in human breast milk. In lactating rats, sofosbuvir was detected in milk at concentrations similar to maternal plasma. The M/P ratio in rats was approximately 1.0. The pharmacokinetics in nursing infants have not been evaluated. Because of the potential for adverse reactions in breastfed infants, and because ribavirin (if coadministered) is contraindicated during lactation, breastfeeding is not recommended during treatment with Sovaldi. The CDC recommends that women with chronic HCV can breastfeed, as HCV is not transmitted through breast milk; however, the safety of sofosbuvir during lactation has not been established.
No data on the presence of sofosbuvir or velpatasvir in human milk, effects on the breastfed infant, or milk production. Because of the potential for adverse effects in the breastfed infant, breastfeeding is not recommended during treatment and for 6 months after the last dose, especially if ribavirin is co-administered. M/P ratio: unknown.
No specific dosing adjustments for sofosbuvir are recommended during pregnancy based on pharmacokinetic changes. In animal studies, pharmacokinetics were not significantly altered in pregnant vs non-pregnant animals. However, physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may affect drug disposition, but no clinical data are available to support dose adjustment. If used with ribavirin, ribavirin dose should be based on body weight (1000 mg/day if <75 kg, 1200 mg/day if ≥75 kg, divided twice daily) and adjusted for hematologic toxicity. For severe renal impairment (e GFR <30 m L/min/1.73 m²), sofosbuvir is not recommended due to increased exposure of its metabolite. In all cases, the combination of sofosbuvir with ribavirin is not recommended during pregnancy due to ribavirin's teratogenicity.
No dose adjustment is recommended for EPCLUSA based on pregnancy alone. However, pharmacokinetic changes in pregnancy may alter drug exposure; therapeutic drug monitoring is not currently recommended. Safety and efficacy in pregnant women have not been established.
Sovaldi (sofosbuvir) is a pangenotypic NS5B polymerase inhibitor used in combination with other direct-acting antivirals for chronic hepatitis C. Monitor for bradycardia when coadministered with amiodarone; avoid concurrent use if possible. Renal impairment (e GFR <30 m L/min) is a contraindication due to accumulation of the sofosbuvir metabolite GS-331007. All-oral regimens achieve >95% sustained virologic response. Hepatitis B reactivation risk requires screening and monitoring.
EPCLUSA (sofosbuvir/velpatasvir) is a pangenotypic NS5B polymerase inhibitor and NS5A inhibitor combination for chronic HCV. For decompensated cirrhosis (Child-Pugh B/C), co-administer with ribavirin. Monitor for bradycardia when used with amiodarone; avoid co-administration if possible. Check for polymorphisms at baseline if HCV genotype 3 and cirrhosis (consider extending treatment). Assess renal function; not recommended if e GFR <30 m L/min/1.73m² unless on dialysis and benefit outweighs risk.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor, even if you feel well.,Use effective contraception during treatment and for 30 days after finishing, as ribavirin-containing regimens can cause birth defects.,Report any signs of serious side effects like slow heartbeat (dizziness, fainting) or allergic reactions.,Avoid drinking alcohol as it can worsen liver disease and reduce treatment effectiveness.,Inform your doctor about all medications, including over-the-counter drugs and supplements, to avoid interactions.,You will need regular blood tests to monitor liver function, viral load, and side effects.
Take one tablet (400 mg sofosbuvir/100 mg velpatasvir) orally once daily with or without food.,Complete the full course of treatment (12 weeks for most patients; 24 weeks for genotype 3 with cirrhosis or prior treatment failure).,Use of amiodarone with EPCLUSA can cause serious slowing of heartbeat (bradycardia). Inform your doctor if you take amiodarone.,Avoid taking rifampin, St. John's wort, or certain anticonvulsants (carbamazepine, phenytoin) as they reduce EPCLUSA effectiveness.,Report any symptoms of hepatitis B reactivation (fatigue, jaundice, dark urine) immediately.,If you have diabetes, monitor blood glucose closely as treatment may improve glucose control.,Use effective contraception during treatment and for 6 months after if using combined oral contraceptives containing ethinyl estradiol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOVALDI vs EPCLUSA, answered by our medical review team.
SOVALDI is a Direct-acting antiviral that works by Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is converted to the active triphosphate form (GS-461203) that competes with natural nucleotides and causes chain termination upon incorporation into viral RNA.. EPCLUSA is a Direct-Acting Antiviral (DAA) for Hepatitis C that works by EPCLUSA is a fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor. Sofosbuvir inhibits HCV RNA replication by acting as a chain terminator, while velpatasvir inhibits HCV replication by binding to NS5A and disrupting viral RNA replication and assembly.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOVALDI and EPCLUSA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOVALDI is: 400 mg orally once daily with or without food.. The standard adult dose of EPCLUSA is: 400 mg sofosbuvir / 100 mg velpatasvir orally once daily with or without food for 12 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOVALDI and EPCLUSA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOVALDI is classified as Category C. Sovaldi (sofosbuvir) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity at exposures up to 10 times the human therapeutic dose. Howe. EPCLUSA is classified as Category C. EPCLUSA (sofosbuvir/velpatasvir) is contraindicated in pregnancy due to the teratogenic risk associated with ribavirin (if used in combination). In the absence of ribavirin, there . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.